Myasthenic Syndrome, Congenital, 6, Presynaptic (CMS6)

External Ids:

Disease Ontology 12 DOID:0110671 OMIM® 57 254210 OMIM Phenotypic Series 57 PS601462 MeSH 44 D020294

MedGen 41 C0393929 SNOMED-CT via HPO 68 111246005 11934000 128602000 2120003 22066006 230145002 258211005 267036007 271825005 288939007 398432008 40739000 77016009 more UMLS 70 C0393929

UniProtKB/Swiss-Prot : ⁷² Myasthenic syndrome, congenital, 6, presynaptic: A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre- synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS6 affected individuals have myasthenic symptoms since birth or early infancy, negative tests for anti-AChR antibodies, and abrupt episodic crises with increased weakness, bulbar paralysis, and apnea precipitated by undue exertion, fever, or excitement. CMS6 inheritance is autosomal recessive.

MalaCards based summary : Myasthenic Syndrome, Congenital, 6, Presynaptic, also known as familial infantile myasthenia, is related to congenital myasthenic syndrome with episodic apnea and fallopian tube carcinoma, and has symptoms including apnea, ophthalmoparesis and respiratory distress. An important gene associated with Myasthenic Syndrome, Congenital, 6, Presynaptic is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are DNA Damage and BRCA1 Pathway. Affiliated tissues include eye, breast and ovary, and related phenotypes are ptosis and dysphagia

Disease Ontology : ¹² A congenital myasthenic syndrome characterized by autosomal recessive inheritance of a presynaptic defect resulting in onset of muscle weakeness in infancy or early childhood and a tendency to have sudden apneic episodes that has material basis in homozygous or compound heterozygous mutation in the CHAT gene on chromosome 10q.

OMIM® : ⁵⁷ Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting the neuromuscular junction (NMJ). Patients present clinically with onset of variable muscle weakness between infancy and adulthood. These disorders have been classified according to the location of the defect: presynaptic, synaptic, and postsynaptic. CMS6 is an autosomal recessive CMS resulting from a presynaptic defect; patients have onset of symptoms in infancy or early childhood and tend to have sudden apneic episodes. Treatment with acetylcholinesterase inhibitors may be beneficial (summary by Engel et al., 2015). For a discussion of genetic heterogeneity of CMS, see CMS1A (601462). (254210) (Updated 20-May-2021)

Clinical features from OMIM®:

254210 (Updated 20-May-2021)

Search Clinical Trials , NIH Clinical Center for Myasthenic Syndrome, Congenital, 6, Presynaptic

Search GEO for disease gene expression data for Myasthenic Syndrome, Congenital, 6, Presynaptic.